Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Atracurium, Tracrium; Belgium: Tracrium; Bulgaria: Tracrium; Cyprus: Tracrium; Czech Republic: Tracrium; Estonia: Tracrium; France: Atracurium, Tracrium; Germany: Atracurium, Tracrium; Greece: Tracrium; Hungary: Tracrium; Ireland: Atracurium; Italy: Acurmil, Atracurio, Atracurium, Tracrium; Latvia: Tracrium; Lithuania: Tracrium; Luxembourg: Tracrium; Malta: Tracrium; Netherlands: Atracurium, Tracrium; Poland: Tracrium; Portugal: Tracrium; Romania: Tracrium; Slovakia: Tracrium; Slovenia: Tracrium; Spain: Atracurio, Tracrium; Sweden: Atracurium, Tracrium; UK: Atracurium, Tracrium.

North America

Canada: Atracurium; USA: Atracurium, Tracrium.

Latin America

Argentina: Atracurio, Atracurium, Gelolagar, Tracrium, Tracurix, Tracuron; Brazil: Abbottracurium, Atracúrio, Tracrium, Tracur; Mexico: Relatrac, Trablok, Tracrium.

Drug combinations


Atracurium Besylate: C~65~H~82~N~2~O~18~S~2~. Mw: 1243.48. (1) Isoquinolinium, 2,2′-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate; (2) 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester. CAS-64228-81-5 (1983).

Pharmacologic Category

Skeletal Muscle Relaxants; Neuromuscular Blocking Agents, Nondepolarizing. (ATC-Code: M03AC04).

Mechanism of action

Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites.

Therapeutic use

Endotracheal intubation and relaxation of skeletal muscles during surgery (adjunct to general anesthesia). Mechanical ventilation in intensive care unit.

Pregnancy and lactiation implications

Use with caution during pregnancy or lactation.

Unlabeled use


Hypersensitivity to atracurium or any component of the formulation.

Warnings and precautions

Bradycardia. Cross-sensitivity with other neuromuscular-blocking agents (use extreme caution in previous anaphylactic reactions). Resistance is possible in burn patients. The following conditions may antagonize neuromuscular blockade: alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, or diabetes mellitus. The following conditions may potentiate neuromuscular blockade: electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, or hepatic failure. Use with caution in the elderly. Resistance may develop in immobilized patients or with chronic treatment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart